Adicet Bio to Participate in Upcoming Investor Conferences

ACET 11.01.2024

Full Press ReleaseSEC FilingsOur ACET Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
  • 12.31.2024 - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
  • 12.19.2024 - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Recent Filings

  • 12.19.2024 - EX-99.1 EX-99.1
  • 12.19.2024 - 8-K Current report
PDF Version

REDWOOD CITY, Calif.&BOSTON--(BUSINESS WIRE)--Nov. 1, 2024--Adicet Bio, Inc.(Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November.

Details of the events are as follows:

Truist Securities BioPharma Symposium,November 7, 2024,New York, NY

  • Members of management will be available for 1x1 meetings onNovember 7, 2024

Guggenheim Securities Healthcare Innovation Conference,November 11-13, 2024,Boston, MA

  • Chen Schor, President and Chief Executive Officer, will participate in a fireside chat onNovember 12, 2024at3:00 p.m. ET

Jefferies London Healthcare Conference,November 19-21, 2024,London

  • Chen Schor, President and Chief Executive Officer, will participate in a fireside chat onNovember 19, 2024at12:30 p.m. BST

The live audio webcasts of the fireside chats can be accessed on the Investors section of Adicet Bio’s website athttp://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

AboutAdicet Bio, Inc.

Adicet Bio, Inc.is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website athttps://www.adicetbio.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241101153157/en/

Adicet Bio, Inc.Investor and Media Contacts

Investors:Anne Bowdidgeabowdidge@adicetbio.com

Janhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com

Media:Kerry Beth Dalykbdaly@adicetbio.com

Source:Adicet Bio, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com